13F filer · CIK 1422848 ↗

Capital Research Global Investors

You are looking at Q3 2017. See the latest, Q2 2026 →

Reported value

$331.24B

+3.7% on the quarter before

Positions

432

33 new · 32 sold out

Top 10

24.9%

of the value

Est. gain

+$15.05B

on stocks held all quarter

Est. return

+5.1%

on those stocks since Q2 2017

Filed

Nov 14, 2017

On SEC EDGAR ↗

Positions as of Sep 30, 2017, from Capital Research Global Investors's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

The 24 largest positions, 42% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2017. Striped tiles are options.

Abbvie Inc5.1%

Amazon3.1%

Amgen Inc3.0%

Netflix2.6%

Verizon Communications Inc2.4%

Broadcom Ltd2.0%

Microsoft1.8%Intel1.7%

Philip Morris International1.7%

Alibaba1.7%

Csx Corp1.6%

Alphabet1.5%

Eog Resources Inc1.3%

Stryker Corp1.3%

Apple1.3%Oracle1.3%Alphabet1.3%Texas Instruments1.2%

Unitedhealth Group Inc1.2%

Accenture Plc Cl A1.2%

Abbott Laboratories1.1%

American International Group Inc1.1%

General Dynamics Corp1.1%

Thermo Fisher Scientific Inc1.1%

Abbvie Inc5.1%

Amazon3.1%

Amgen Inc3.0%

Netflix2.6%

Verizon Communications Inc2.4%

Broadcom Ltd2.0%

Microsoft1.8%Intel1.7%

Philip Morris International1.7%

Alibaba1.7%

Csx Corp1.6%

Alphabet1.5%

Eog Resources Inc1.3%

Stryker Corp1.3%

Apple1.3%Oracle1.3%Alphabet1.3%Texas Instruments1.2%

Unitedhealth Group Inc1.2%

Accenture Plc Cl A1.2%

Abbott Laboratories1.1%

American International Group Inc1.1%

General Dynamics Corp1.1%

Thermo Fisher Scientific Inc1.1%

Largest buys

Since Q2 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Vale Sa On ADR~$1.61BAdded · 0.0% → 0.5%+159,893,564 shares
Abbott Laboratories~$1.08BAdded · 0.7% → 1.1%+20,271,463 shares
Dowdupont Inc~$1.01BNew · 0.0% → 0.3%+14,556,350 shares
British American Tobacco Plc ADR~$970.9MNew · 0.0% → 0.3%+15,546,114 shares
Abbvie Inc~$954.4MAdded · 4.0% → 5.1%+10,740,344 shares
General Electric Co~$921.4MAdded · 0.8% → 0.9%+38,107,775 shares
Intel~$875.8MAdded · 1.4% → 1.7%+22,998,634 shares
Csx Corp~$837.9MAdded · 1.4% → 1.6%+15,441,575 shares
Charles Schwab Corp~$813.9MAdded · 0.3% → 0.6%+18,607,350 shares
Microsoft~$763.9MAdded · 1.5% → 1.8%+10,255,438 shares

Largest sells

Since Q2 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Oracle~$2.54BCut · 2.2% → 1.3%−52,530,301 shares
Reynolds American Inc (Not Listed Or Trading)~$1.97BSold out · 0.6% → 0.0%−30,352,214 shares
Vale Sa Pna ADR~$1.39BSold out · 0.4% → 0.0%−170,906,607 shares
Texas Instruments~$1.11BCut · 1.4% → 1.2%−12,367,818 shares
Boeing Co~$1.07BCut · 0.8% → 0.6%−4,210,483 shares
Dow Chemical Co~$918.2MSold out · 0.3% → 0.0%−14,557,662 shares
Altria Group Inc~$762.4MCut · 1.3% → 0.9%−12,020,659 shares
Union Pacific Corp~$728.0MCut · 1.0% → 0.8%−6,277,576 shares
Broadcom Ltd~$724.7MCut · 2.2% → 2.0%−2,988,008 shares
Kite Pharma Inc~$719.1MSold out · 0.2% → 0.0%−6,936,691 shares

Holdings

As of Sep 30, 2017. Changes are in shares against Jun 30, 2017, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Abbvie IncCOMMON STOCK · shares +6.0% · price +22.5%	5.1%	4.0%	$16.80B	189.0M	+6.0%	$88.86	$72.51	+22.5%	+$2.91B
2	AmazonCOMMON STOCK · shares −0.9% · price −0.7%	3.1%	3.2%	$10.21B	10.6M	−0.9%	$961.35	$968.00	−0.7%	−$70.6M
3	Amgen IncCOMMON STOCK · shares −2.4% · price +8.3%	3.0%	2.9%	$9.79B	52.5M	−2.4%	$186.45	$172.23	+8.3%	+$746.3M
4	NetflixCOMMON STOCK · shares −3.6% · price +21.4%	2.6%	2.3%	$8.51B	46.9M	−3.6%	$181.35	$149.41	+21.4%	+$1.50B
5	Verizon Communications IncCOMMON STOCK · shares +3.6% · price +10.8%	2.4%	2.1%	$7.87B	158.9M	+3.6%	$49.49	$44.66	+10.8%	+$741.0M
6	Broadcom LtdCOMMON STOCK · shares −10% · price +4.1%	2.0%	2.2%	$6.47B	26.7M	−10%	$242.54	$233.05	+4.1%	+$253.0M
7	MicrosoftCOMMON STOCK · shares +15% · price +8.1%	1.8%	1.5%	$5.95B	79.9M	+15%	$74.49	$68.93	+8.1%	+$387.3M
8	IntelCOMMON STOCK · shares +18% · price +12.9%	1.7%	1.4%	$5.77B	151.6M	+18%	$38.08	$33.74	+12.9%	+$558.0M
9	Philip Morris InternationalCOMMON STOCK · shares −11% · price −5.5%	1.7%	2.1%	$5.74B	51.7M	−11%	$111.01	$117.45	−5.5%	−$333.1M
10	AlibabaCOMMON STOCK · shares −4.8% · price +22.6%	1.7%	1.5%	$5.53B	32.0M	−4.8%	$172.71	$140.90	+22.6%	+$1.02B
11	Csx CorpCOMMON STOCK · shares +19% · price −0.5%	1.6%	1.4%	$5.30B	97.7M	+19%	$54.26	$54.56	−0.5%	−$24.7M
12	AlphabetCOMMON STOCK · shares +1.8% · price +5.5%	1.5%	1.4%	$4.87B	5.1M	+1.8%	$959.11	$908.73	+5.5%	+$251.1M
13	Eog Resources IncCOMMON STOCK · shares +8.4% · price +6.9%	1.3%	1.2%	$4.39B	45.3M	+8.4%	$96.74	$90.52	+6.9%	+$260.2M
14	Stryker CorpCOMMON STOCK · shares +0.3% · price +2.3%	1.3%	1.3%	$4.38B	30.9M	+0.3%	$142.02	$138.78	+2.3%	+$99.7M
15	AppleCOMMON STOCK · shares −5.1% · price +7.0%	1.3%	1.3%	$4.31B	28.0M	−5.1%	$154.12	$144.02	+7.0%	+$282.4M
16	OracleCOMMON STOCK · shares −37% · price −3.6%	1.3%	2.2%	$4.29B	88.7M	−37%	$48.35	$50.14	−3.6%	−$158.9M
17	AlphabetCOMMON STOCK · shares +0.2% · price +4.7%	1.3%	1.3%	$4.20B	4.3M	+0.2%	$973.72	$929.68	+4.7%	+$189.7M
18	Texas InstrumentsCOMMON STOCK · shares −21% · price +16.5%	1.2%	1.4%	$4.07B	45.4M	−21%	$89.64	$76.93	+16.5%	+$576.5M
19	Unitedhealth Group IncCOMMON STOCK · shares −6.1% · price +5.6%	1.2%	1.3%	$4.01B	20.5M	−6.1%	$195.85	$185.42	+5.6%	+$213.8M
20	Accenture Plc Cl ACOMMON STOCK · shares +0.5% · price +9.2%	1.2%	1.1%	$3.87B	28.7M	+0.5%	$135.07	$123.68	+9.2%	+$324.6M
21	Abbott LaboratoriesCOMMON STOCK · shares +43% · price +9.8%	1.1%	0.72%	$3.62B	67.9M	+43%	$53.36	$48.61	+9.8%	+$226.1M
22	American International Group IncCOMMON STOCK · shares −0.00% · price −1.8%	1.1%	1.1%	$3.53B	57.6M	−0.00%	$61.39	$62.52	−1.8%	−$65.0M
23	General Dynamics CorpCOMMON STOCK · shares +1.5% · price +3.8%	1.1%	1.0%	$3.50B	17.0M	+1.5%	$205.58	$198.10	+3.8%	+$125.6M
24	Thermo Fisher Scientific IncCOMMON STOCK · shares +6.5% · price +8.4%	1.1%	0.94%	$3.49B	18.4M	+6.5%	$189.20	$174.47	+8.4%	+$254.9M
25	Canadian Natural Resources LtdCOMMON STOCK · shares +3.1% · price +16.1%	1.0%	0.88%	$3.37B	100.7M	+3.1%	$33.49	$28.85	+16.1%	+$452.8M
	Total · 432 positions	100%		$331.24B						+$15.05B

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2017 to Q3 2017: 396 stocks held throughout, up $15.05B (+5.1%).

Abbvie Inc+$2.91B+23%
Netflix+$1.50B+21%
Alibaba+$1.02B+23%
Amgen Inc+$746.3M+8%
Verizon Communications Inc+$741.0M+11%
General Electric Co−$258.1M−10%
Medtronic Plc−$322.3M−12%
Philip Morris International−$333.1M−5%
Altria Group Inc−$500.4M−15%
Teva Pharmaceutical Industries Ltd ADR−$1.09B−47%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$800.00B$400.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 12, 2026	$716.87B+11%	426	SEC ↗
Q1 2026	May 13, 2026	$644.56B+19%	459	SEC ↗
Q4 2025	Feb 11, 2026	$541.73B+2%	434	SEC ↗
Q3 2025	Nov 13, 2025	$532.97B+7%	433	SEC ↗
Q2 2025	Aug 13, 2025	$499.46B+9%	431	SEC ↗
Q1 2025	May 12, 2025	$459.90B−5%	456	SEC ↗
Q4 2024	Feb 13, 2025	$486.38B+1%	438	SEC ↗
Q3 2024	Nov 13, 2024	$481.14B+6%	415	SEC ↗
Q2 2024	Aug 13, 2024	$455.74B+3%	414	SEC ↗
Q1 2024	May 14, 2024	$441.98B+9%	410	SEC ↗
Q4 2023	Feb 13, 2024	$406.47B+12%	408	SEC ↗
Q3 2023	Nov 13, 2023	$363.16B−3%	411	SEC ↗
Q2 2023	Aug 11, 2023	$373.18B+7%	414	SEC ↗
Q1 2023	May 15, 2023	$350.40B+6%	425	SEC ↗
Q4 2022	Feb 14, 2023	$330.88B+9%	436	SEC ↗
Q3 2022	Nov 14, 2022	$304.37B−5%	429	SEC ↗
Q2 2022	Aug 15, 2022	$321.05B−21%	423	SEC ↗
Q1 2022	May 19, 2022 (amended)	$405.10B−11%	440	SEC ↗
Q4 2021	Feb 14, 2022	$452.67B+6%	440	SEC ↗
Q3 2021	Nov 15, 2021	$428.65B−0%	441	SEC ↗
Q2 2021	Aug 16, 2021	$429.52B+5%	436	SEC ↗
Q1 2021	May 14, 2021	$408.71B+6%	425	SEC ↗
Q4 2020	Feb 12, 2021	$385.30B+16%	404	SEC ↗
Q3 2020	Nov 13, 2020	$333.11B+5%	405	SEC ↗
Q2 2020	Aug 14, 2020	$316.13B+24%	399	SEC ↗
Q1 2020	May 15, 2020	$254.90B−24%	397	SEC ↗
Q4 2019	Feb 18, 2020	$333.48B+9%	405	SEC ↗
Q3 2019	Nov 14, 2019	$304.85B−3%	414	SEC ↗
Q2 2019	Aug 14, 2019	$314.99B−0%	401	SEC ↗
Q1 2019	May 15, 2019	$315.45B+10%	415	SEC ↗
Q4 2018	Feb 14, 2019	$287.02B−17%	417	SEC ↗
Q3 2018	Nov 14, 2018	$344.02B−6%	436	SEC ↗
Q2 2018	Aug 14, 2018	$366.12B+4%	440	SEC ↗
Q1 2018	May 15, 2018	$351.43B+3%	443	SEC ↗
Q4 2017	Feb 14, 2018	$340.76B+3%	432	SEC ↗
Q3 2017	Nov 14, 2017	$331.24B+4%	432	SEC ↗
Q2 2017	Aug 14, 2017	$319.49B+1%	431	SEC ↗
Q1 2017	May 15, 2017	$317.04B+3%	425	SEC ↗
Q4 2016	Feb 15, 2017	$308.47B+2%	427	SEC ↗
Q3 2016	Nov 14, 2016	$302.53B+3%	413	SEC ↗
Q2 2016	Aug 15, 2016	$292.47B+1%	419	SEC ↗
Q1 2016	May 16, 2016	$290.06B	430	SEC ↗